Home News International


Elder Pharma to focus on anti-infectives, international market

New Delhi December 27, 2013: After selling its branded formulation business, Elder Pharma plans to focus on its anti-infectives’ vertical and strengthen in-licence portfolio besides looking at expanding presence in global markets. “Post the deal with Torrent Pharma, Elder...

New draft guidance has been released by the US medical device regulators

US November 18, 2013: New draft guidance has been released by the US medical device regulators, which is related to requirements for manufacturers and marketers of hearing aids and personal sound amplification products (PSAPs). According to the new draft,...

AstraZeneca launches its patented life-saving heart drug BRILINTA® (Ticagrelor) in India

AstraZeneca Pharma India Limited (AZPIL) today announced the launch of a new patented antiplatelet drug BRILINTA® (Ticagrelor) in India. BRILINTA® is an oral antiplatelet treatment for Acute Coronary Syndromes (ACS) in adult patients. BRILINTA® is competitively priced to enable ACS patients benefit from having access to this medicine.

BRILINTA® works by preventing the formation of new blood clots and maintaining blood flow in the body to help reduce patient’s risk of another cardiovascular event (called atherothrombotic events) such as a heart attack or cardiovascular death.

Taro Provides Third Quarter and Fiscal Year to Date Results

Favorable Performance Over 2011 Periods Continues

Hawthorne, New York, United States, Tuesday, February 05, 2013 -- (Business Wire India) –

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) ("Taro" or the "Company") today provided unaudited financial results for the three and nine month periods ended December 31, 2012.

Watson Pharmaceuticals

Watson Confirms Velcade® Patent Challenge

Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that Actavis, Inc., which was acquired by Watson in October, has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market bortezomib.

Actavis' ANDA product is a generic version of Millennium Pharmaceuticals' Velcade ® (bortezomib), which is a proteasome inhibitor, for intravenous or subcutaneous administration, approved for the treatment of patients with multiple myeloma and patients with mantle cell lymphoma who have received at least one prior therapy.

Dabur promoter Burmans enter healthcare, partner UK firm

New Delhi November 30, 2013: The promoter of FMCG major Dabur India, the Burman family is foraying into healthcare space in the country and has formed a joint venture with founders of UK-based 'Healthcare At Home' with plans to...

International medical fair opens in Mumbai Friday

New Delhi, March 13,2014: More than 450 exhibitors from 20 countries and over 8,000 visitors from 22 countries are expected to take part in the trade fair, organisers said. The 20th Medical Fair India 2014 (MFI 2014), the country's...

Sun Pharma and Taro Announce Termination of Proposed Transaction

Hawthorne, New York, United States and Mumbai, Maharashtra, India, Monday, February 11, 2013 -- (Business Wire India) –

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) ("Taro") and Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) (together with its subsidiaries, "Sun Pharma") has announced that they have mutually agreed to terminate their merger agreement, announced in August 2012, pursuant to which all shareholders of Taro (other than Sun Pharma and its affiliates) would have received a cash payment of $39.50 per share upon the closing of the merger.

Watson Completes Actavis Acquisition

Creates 3rd largest global generics company with presence in 60+ markets$8.0+ billion anticipated pro forma combined 2012 revenueCombined management structured to immediately maximize combination value

PARSIPPANY, N.J. – October 31, 2012 – Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that it has completed the acquisition of the Actavis Group for EUR4.25 billion. The combination creates the world’s third largest generic pharmaceutical company, with anticipated pro forma combined 2012 revenues in excess of $8 billion.

Glenmark’s new pain management molecule to enter human trials in UK

Mumbai, April 04,2014 : Drug maker Glenmark Pharmaceuticals Ltd’s pain management drug candidate, GRC 27864, is entering human trials in the UK.  The company has already completed preclinical and phase-1 enabling studies on the newly discovered molecule and...